FY2025 EPS Estimates for BBIO Raised by Cantor Fitzgerald

BridgeBio Pharma, Inc. (NASDAQ:BBIO) – Cantor Fitzgerald upped their FY2025 earnings per share (EPS) estimates for shares of BridgeBio Pharma in a report released on Thursday, October 30th. Cantor Fitzgerald analyst J. Schimmer now anticipates that the company will post earnings per share of ($3.52) for the year, up from their previous forecast of ($3.57). Cantor Fitzgerald has a “Overweight” rating and a $110.00 price objective on the stock. The consensus estimate for BridgeBio Pharma’s current full-year earnings is ($3.67) per share. Cantor Fitzgerald also issued estimates for BridgeBio Pharma’s FY2026 earnings at ($2.07) EPS.

BridgeBio Pharma (NASDAQ:BBIO) last issued its earnings results on Wednesday, October 29th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.07). The business had revenue of $108.11 million during the quarter, compared to analyst estimates of $107.71 million. During the same period in the prior year, the company posted ($0.86) EPS. The firm’s revenue for the quarter was up 4318.0% compared to the same quarter last year.

Several other analysts have also recently issued reports on BBIO. TD Cowen increased their target price on shares of BridgeBio Pharma from $60.00 to $95.00 and gave the stock a “buy” rating in a research note on Thursday, October 30th. Oppenheimer increased their target price on shares of BridgeBio Pharma from $60.00 to $61.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 6th. Evercore ISI reiterated an “outperform” rating on shares of BridgeBio Pharma in a research note on Monday, October 27th. Cowen reiterated a “positive” rating on shares of BridgeBio Pharma in a research note on Thursday. Finally, Citigroup lifted their price target on BridgeBio Pharma from $58.00 to $67.00 and gave the company a “buy” rating in a research report on Friday, July 11th. Twenty investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $73.58.

BridgeBio Pharma Stock Down 1.1%

Shares of NASDAQ BBIO opened at $61.98 on Monday. BridgeBio Pharma has a 52 week low of $21.72 and a 52 week high of $69.48. The business has a 50-day simple moving average of $54.21 and a two-hundred day simple moving average of $45.89. The company has a market cap of $11.94 billion, a P/E ratio of -14.83 and a beta of 1.39.

Hedge Funds Weigh In On BridgeBio Pharma

Institutional investors and hedge funds have recently made changes to their positions in the business. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in shares of BridgeBio Pharma during the 2nd quarter valued at $25,000. First Horizon Corp bought a new position in shares of BridgeBio Pharma during the 3rd quarter valued at $36,000. AlphaQuest LLC grew its holdings in shares of BridgeBio Pharma by 254.3% during the 3rd quarter. AlphaQuest LLC now owns 815 shares of the company’s stock valued at $42,000 after purchasing an additional 585 shares during the last quarter. GAMMA Investing LLC increased its stake in BridgeBio Pharma by 71.0% in the 1st quarter. GAMMA Investing LLC now owns 920 shares of the company’s stock worth $32,000 after purchasing an additional 382 shares during the period. Finally, Jones Financial Companies Lllp purchased a new position in BridgeBio Pharma in the 1st quarter worth approximately $35,000. Institutional investors own 99.85% of the company’s stock.

Insider Transactions at BridgeBio Pharma

In related news, CEO Neil Kumar sold 40,000 shares of the firm’s stock in a transaction dated Thursday, August 7th. The stock was sold at an average price of $45.45, for a total transaction of $1,818,000.00. Following the transaction, the chief executive officer directly owned 935,686 shares of the company’s stock, valued at approximately $42,526,928.70. This trade represents a 4.10% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Frank Mccormick sold 198,359 shares of the firm’s stock in a transaction dated Wednesday, October 29th. The shares were sold at an average price of $66.58, for a total value of $13,206,742.22. Following the transaction, the director directly owned 679,979 shares in the company, valued at approximately $45,273,001.82. This represents a 22.58% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 780,746 shares of company stock valued at $41,506,451. 18.20% of the stock is currently owned by corporate insiders.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.